Pharmaceutical Technology

SEPTEMBER 23, 2022

The recent FDA approval of Fennec Pharmaceuticals’ drug PEDMARK (sodium thiosulfate injection) marks a significant advance for cancer treatment-associated hearing loss therapies, amidst a bid to improve quality of life for cancer patients. The current standard of care for many cancers is cisplatin chemotherapy or platinum therapy.

FDA 52

FDA Communication Chemotherapy Labelling 52

The Checkup by Singlecare

OCTOBER 16, 2023

Food and Drug Administration (FDA) in 2004 , Cymbalta has become a widely used antidepressant to treat various mental health and pain-related conditions. What Are the Off-Label Uses for Cymbalta? Cymbalta may have several off-label uses in addition to its FDA-approved uses. Approved by the U.S.

Dosage 52

Dosage Insurance Coverage Labelling Insurance 52

The Checkup by Singlecare

OCTOBER 27, 2023

How to minimize amoxicillin-potassium clavulanate interactions Your best bet to avoid drug-drug interactions involving amoxicillin-potassium clavulanate is to communicate well with your medical providers.

Adverse Reactions 52

Adverse Reactions Labelling Chemotherapy Communication 52

ISPE

MAY 10, 2023

Mexican Governor: Cancer Children Given Water Instead of Chemotherapy.” 3M explores New Label-As-A-Service Concept with Blockchain on Azure to Stop Counterfeit Pharmaceuticals.” You may unsubscribe from these ISPE communications at any time. 30 June 2016. link] 6 BBC News. Published 19 January 2017. link] 7 He, J., Cai, and X.

Dosage 52

Dosage Chemotherapy Documentation Labelling 52

Pharmaceutical Technology

JUNE 16, 2023

Merck ( MSD ) has announced updated results with Keytruda (pembrolizumab) in the Phase III Keynote-811 trial, which opens up the possibility of changing the checkpoint inhibitor’s label in HER2-positive gastric or GEJ adenocarcinoma so it’s based on the tumour’s PD-L1 biomarker status. Please check your email to download the Report.

Chemotherapy 52

Chemotherapy Labelling FDA Communication 52

Pharmaceutical Technology

JUNE 16, 2023

Synthetic biology biopharma Biostar Pharma announced is ready to advance its utidelone injectable (UTD1) in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC), following approval from the US Food and Drug Administration (FDA) for the study. as the secondary endpoints. ORR, 81.0% DCR (disease control rate), 4.37

FDA 52

FDA Chemotherapy Labelling Pharmaceutical Companies 52

Pharmaceutical Technology

FEBRUARY 27, 2023

The ADC is already approved in the metastatic setting after chemotherapy or in the case of disease recurrence during or in six months after adjuvant chemotherapy. Regulatory decisions by the US FDA for select therapies from late December to late January, and the CMOs contracted to manufacture them.

Packaging 52

Packaging Chemotherapy FDA Labelling 52